157 related articles for article (PubMed ID: 17495412)
1. SNP communications: coalition of toxicology and drug metabolism and pharmacokinetics.
Ikeda T
Drug Metab Pharmacokinet; 2007 Apr; 22(2):65-6. PubMed ID: 17495412
[No Abstract] [Full Text] [Related]
2. [Drug-induced liver injury].
Ikeda T
Nihon Yakurigaku Zasshi; 2006 Jun; 127(6):454-9. PubMed ID: 16880695
[No Abstract] [Full Text] [Related]
3. Troglitazone.
Yokoi T
Handb Exp Pharmacol; 2010; (196):419-35. PubMed ID: 20020270
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone and liver injury: in search of answers.
Chojkier M
Hepatology; 2005 Feb; 41(2):237-46. PubMed ID: 15657914
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
Ott P; Ranek L; Young MA
Eur J Clin Pharmacol; 1998 Sep; 54(7):567-71. PubMed ID: 9832300
[TBL] [Abstract][Full Text] [Related]
6. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
Gitlin N; Julie NL; Spurr CL; Lim KN; Juarbe HM
Ann Intern Med; 1998 Jul; 129(1):36-8. PubMed ID: 9652997
[No Abstract] [Full Text] [Related]
7. FDA reviews troglitazone.
Donnelly R
Diabetes Obes Metab; 1999 Mar; 1(2):65-6. PubMed ID: 11220513
[No Abstract] [Full Text] [Related]
8. Mechanisms of troglitazone hepatotoxicity.
Smith MT
Chem Res Toxicol; 2003 Jun; 16(6):679-87. PubMed ID: 12807350
[No Abstract] [Full Text] [Related]
9. Drug-induced hepatotoxicity.
Lee WM
N Engl J Med; 2003 Jul; 349(5):474-85. PubMed ID: 12890847
[No Abstract] [Full Text] [Related]
10. Severe but reversible hepatitis induced by troglitazone.
Schiano T; Dolehide K; Hart J; Baker AL
Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
[No Abstract] [Full Text] [Related]
11. Avoiding hepatic injury from drugs.
Kaplowitz N
Gastroenterology; 1999 Oct; 117(4):759. PubMed ID: 10500055
[No Abstract] [Full Text] [Related]
12. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone-associated hepatic failure.
Misbin RI
Ann Intern Med; 1999 Feb; 130(4 Pt 1):330. PubMed ID: 10068399
[No Abstract] [Full Text] [Related]
14. Hepatic injury due to troglitazone.
Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF
Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637
[No Abstract] [Full Text] [Related]
15. Rapid-onset subfulminant liver failure associated with troglitazone.
Jagannath S; Rai R
Ann Intern Med; 2000 Apr; 132(8):677. PubMed ID: 10766693
[No Abstract] [Full Text] [Related]
16. A Japanese case of liver dysfunction after 19 months of troglitazone treatment.
Iwase M; Yamaguchi M; Yoshinari M; Okamura C; Hirahashi T; Tsuji H; Fujishima M
Diabetes Care; 1999 Aug; 22(8):1382-4. PubMed ID: 10480795
[No Abstract] [Full Text] [Related]
17. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Maniratanachote R; Shibata A; Kaneko S; Yamamori I; Wakasugi T; Sawazaki T; Katoh K; Tokudome S; Nakajima M; Yokoi T
Toxicology; 2005 Dec; 216(1):15-23. PubMed ID: 16115720
[TBL] [Abstract][Full Text] [Related]
18. Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety.
Young MA; Lettis S; Eastmond R
J Clin Pharmacol; 1998 Sep; 38(9):819-24. PubMed ID: 9753210
[TBL] [Abstract][Full Text] [Related]
19. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Lenhard MJ; Funk WB
Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222
[No Abstract] [Full Text] [Related]
20. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.
Kassahun K; Pearson PG; Tang W; McIntosh I; Leung K; Elmore C; Dean D; Wang R; Doss G; Baillie TA
Chem Res Toxicol; 2001 Jan; 14(1):62-70. PubMed ID: 11170509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
